Free Trial

NeuroPace Q4 2024 Earnings Report

NeuroPace logo
$13.11 +0.82 (+6.67%)
As of 04/1/2025 04:00 PM Eastern

NeuroPace EPS Results

Actual EPS
-$0.18
Consensus EPS
-$0.25
Beat/Miss
Beat by +$0.07
One Year Ago EPS
N/A

NeuroPace Revenue Results

Actual Revenue
$21.47 million
Expected Revenue
$21.14 million
Beat/Miss
Beat by +$322.00 thousand
YoY Revenue Growth
N/A

NeuroPace Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Remove Ads

NeuroPace Earnings Headlines

New “Trump” currency proposed in DC
According to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America.
NeuroPace reports Q4 EPS (18c), consensus (22c)
See More NeuroPace Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NeuroPace? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NeuroPace and other key companies, straight to your email.

About NeuroPace

NeuroPace (NASDAQ:NPCE) operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

View NeuroPace Profile

More Earnings Resources from MarketBeat